The pharmaceutical community is excited by retatrutide, a novel dual GIP and GLP-1 target that’s showing significant results in preliminary studies . This treatment works by mimicking natural hormones to impact appetite and promote feelings of fullness , ultimately leading considerable weight loss . While currently under review and not broadly a… Read More